Edwards Q3 2026 Earnings Call: Awaiting Details, Thesis Unchanged

What happened

Edwards Lifesciences held its Q3 2026 earnings call, but the Seeking Alpha article is only a placeholder with no transcript content, leaving the specific results and guidance unknown. Based on the DeepValue master report, the company entered 2026 with strong momentum from Q3 2025, when TAVR growth accelerated to 12.4% and management raised 2026 EPS guidance to $2.90–3.05, driven by asymptomatic TAVR adoption and rapid TMTT scaling. The master report also highlighted key risks, including FTC antitrust constraints after the blocked JenaValve acquisition, recurring quality issues, and the need for TMTT to hit $740–780M in 2026 to validate its second growth engine. Without the transcript, we cannot confirm whether Q3 2026 results aligned with the base-case scenario of 6–8% TAVR growth and ~$750M TMTT revenue. Investors should treat the call as a potential catalyst but await concrete details before reassessing the thesis.

Implication

If Q3 2026 results show TAVR growth within 6–8% and TMTT on track for the guided range, the current WAIT rating and $72 entry target remain appropriate, with upside toward $90 only if execution stays flawless. A miss on TAVR growth below 4% or TMTT revenue falling more than 15% below guidance would activate the bear case and justify trimming positions toward the $70 downside scenario. Conversely, a beat driven by faster asymptomatic adoption or TMTT exceeding $800M could push the bull case toward $100, warranting a re-evaluation of the trim price above $96. Given the lack of transcript details, the immediate priority is to monitor for any commentary on payer pushback, competitive dynamics with Abbott, or new regulatory actions. The stock's recovery to ~$84 already prices in much of the good news, so any negative surprise would likely be penalized sharply, making risk management crucial in the near term.

Thesis delta

The new article provides no substantive information beyond the existence of the Q3 2026 earnings call, so the investment thesis remains unchanged from the DeepValue master report. Without actual results or guidance, we cannot determine whether the base, bear, or bull scenario is playing out, and thus the WAIT rating with an attractive entry at $72 and trim above $96 stands. A shift will only occur after the transcript reveals whether TAVR growth, TMTT revenue, and regulatory updates align with or diverge from the master report's projections.